Similarly, in MPN patients the average reduction of mutant JAK2 allele burden during treatment with JAK inhibitors was modest, although a subset of patients achieved partial or complete molecular responses [26, 29, 35, 36]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.